Enveda secures $311M to bring more nature-derived AI drugs into clinical trials

The round valued the AI biotech at $2 billion. It is currently testing drugs that treat skin conditions and preserve weight loss after stopping GLP-1s.

Read the full story at TechCrunch AI ↗

Timeline · 1 report

2026-09-23 19:31 · TechCrunch AI
Enveda secures $311M to bring more nature-derived AI drugs into clinical trials

More stories

GPT-6 Sol and Luna now available on AI Gateway — Vercel Blog
Sam Altman’s remarks at the United Nations Security Council — OpenAI News
Create your own voices with Gemini 3.8 text-to-speech — Google DeepMind YouTube
Google releases Gemini 3.8 Flash TTS and Gemini 3.8 Flash-Lite TTS, its "most expressive audio generation models yet", with support for more than 100 languages (Google) — Techmeme
Anthropic launches Claude Opus 5.5 with stricter safeguards for cybersecurity — The Verge AI
Alibaba unveils new AI chip to challenge NVIDIA, plans Qwen models with up to 10 trillion parameters — Mint AI
No Shirt, No Shoes, No Service: Amazon Blocks Meta’s Muse AI From Shopping — CNET AI
Moonshot’s Kimi K3 lands on Amazon in key test for Chinese open-source AI revenue — South China Morning Post Tech

Get the daily brief of stories like this at 6:30 every morning →